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Chapter 1
Introduction
1.1 Introduction
1.1.1 Overview
Major histocompatibility complexes (MHC) play an integral role in the response of the
immune system. It is the complex that is responsible for recognizing antigenic peptides
and presenting them for the next chain of immune response. There are two major types
of MHC; MHC Class I and Class II (Janeway et al., 2001). These two classes involve
processing and presenting antigens to T lymphocytes but differ in the immune response
pathway. Whilst MHC Class I presents the antigen for recognition of the cytotoxic T
cell, the MHC Class II presents the antigen for recognition of the helper T cell. Studying
the peptides that bind to MHC Class II molecules can facilitate the pipeline for vaccine
design, reducing the number of identifying helper T cell epitopes (Nielsen et al., 2007).
The human counterpart for the MHC Class II is the human leukocyte antigen (HLA) Class
II.
The lengths of MHC Class II binding peptides were known to vary, and several pub-
lications report different ranges. Kato et al. (2003) reported the range as varying from
eleven to thirty residues, whilst Lafuente & Reche (2009) published the range as being
from nine to twenty-two residues. This quality of variable length complicates the process
of building a model that best describes this particular class of binding peptides. Accord-
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ing to structural studies, only a core of nine residues would fit into the MHC binding
groove, this being the peptide-binding core (Lafuente & Reche, 2009). This suggests that
the scoring function for the peptide that binds to the MHC complex is a linear sum of nine
terms (Lund et al., 2005). Therefore, a statistical model which would be able to handle
the variability of the sequence length is needed.
Computer predictions ofMHC-binding peptides can be used as a first screening method
to determine what are the regions on the antigen that will induce a response and hidden
Markov model (HMM) is an example of a stochastic model which has been used to solve
this problem. Profile HMMs can be used to characterize similarities between protein se-
quences (Lund et al., 2005). Homologous sequences may not share many identical amino
acids and the question is how do we detect the similarities. Using information from mul-
tiple sequence alignment that reveals amino acid conservation, mutability and active sites,
profile HMMs puts together all these information to produce the profile for the particular
family of protein (Lund et al., 2005). A question to be asked using HMM is whether a
sequence belongs to a particular family or not. This study aims to study the application
of profile HMM using dataset consisting of peptides that have a high binding affinity for
MHC Class II complexes and to also describe the specificity of the model. The profile
will also be represented using a sequence logo viewer (Schuster-Bockler et al., 2004)
which will provide a graphical representation of the states emitted by the profile HMM.
The profile HMM is then investigated further by searching it against a sequence database.
This is a method which could be used to eliminate peptides which do not fit the profile,
thus reducing the number of potential vaccine candidates.
1.1.2 Objectives of the study
The objective of this project is to study and apply profile HMM-based approach of MHC-
binding peptides from the MHCPEP database (Brusic et al., 1998). The project will focus
on familiarizing with the HMM-based approach using the HMMER3 software package
(Finn et al., 2011) and using dataset of peptides that significantly binds to two types of
human MHC Class II molecule, HLA-DR1 and HLA-DR4.
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1.1.3 Organization of this report
This report is organized as following; the introduction chapter is where I introduce the
basic background of the problem being studied which is the prediction of MHC Class II
binding sites or epitope binding sites as well as the method which I have chosen to tackle
this problem, profile HMM-based approach. After that is the literature review chapter
where I summarize some of the work that has been done in the prediction of MHC Class II
binding sites, including using HMM-based approach. Next is the methods section where I
explain in detail what are the steps I have taken, from pre-processing of dataset to multiple
sequence alignment and building of profile HMM as well as the validation of the profile
HMM. The subsequent chapter are the results where the results of the multiple sequence
alignment, the profile HMM, the HMM logo or the sequence logo, as well as the results
of the validation of the profile HMM is shown. This is then followed by the discussion of
my findings and lastly is the conclusion.
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Chapter 2
Literature Review
The immune system is divided into two types of responses; humoral and cell-mediated
response. The humoral response targets not-self, free-floating objects, or antigens (for-
eign substances not recognized to be naturally in the body which will trigger an immune
response) whilst cell-mediated response is triggered when a cell in the body is attacked
by a pathogen which enters the cell, like a virus. The regulation of the immune response
involves a molecule with the highest degree of polymorphism among mammalian proteins
known as major histocompatibility complex (MHC) (Lund et al., 2005).
The MHC complex regulates the process of immune response by recognizing the pep-
tide that corresponds to the antigen (Mamitsuka, 1998) and are classified into three sub-
groups; MHC Class I, II and III. All the three subgroups of complexes are involved in
certain pathways in the immune response where MHC Class I and II pathways mainly
processes and presents antigens to T lymphocytes (Lund et al., 2005). In the humoral
response, when a lymphocyte (a type of leukocyte, or white blood cell) stumbles upon an
antigen, it will surround and engulf the antigen. The cell’s internal mechanisms will then
chop up the antigen and present a part of the chopped up part on its surface. These cells are
then called antigen presenting cells (APCs) and examples of APCs include macrophages,
dendritic cells, and B-cells. For the purpose of this study, the focus will be on peptides
that interact with the MHC Class II . Figure 2.1 explains a general response involving the
MHC Class II complex when an antigen is detected.
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Figure 2.1: Diagram depicting the humoral response of the immune system. (1) A macrophage is an
example of an antigen presenting cell. (2) Once it detects the pathogens, it will extend its membrane (3)
to engulf the pathogen. (4) Once inside, reactions inside the macrophage will break the pathogen into
fragments, disabling its function. Already present inside the macrophage is a MHC class II molecule.
(5) The MHC class II molecule has a receptor that will recognize the complementary fragment from the
pathogen and will form a MHC complex. (6) The complex will then fuse with the macrophage’s membrane
in order to ’present’ the pathogenic fragment. (7) A T-helper cell with the complementary receptor to the
MHC complex on the macrophage’s membrane. (8) The T-helper cell will bind to the complex and this will
induce the next chain of immunological response to neutralize the pathogens.
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The human counterpart for the MHC molecules are called human leukocyte antigens
(HLA). HLA Class II consists of several supertypes, and are categorized based on the
shared binding characteristic. Examples of the supertypes under the HLA Class II is the
HLA DR, DQ and DP. These supertypes also refer to the alleles which encode for the
HLA molecules.
Investigating peptides that can bind to the MHC molecule, also known as epitope
prediction, is an effective method which can be incorporated into the pipeline for vac-
cine design. Not all peptides will bind to the MHC molecule, and in fact, according to
Mamitsuka (1998), it is said that only about 1 in 100-200 peptides will bind to the MHC
molecule. Experimental methods like synthesizing the peptide and studying the binding
activities can be a laborious and time-consuming process, hence computational methods
can be used to facilitate the process of narrowing down potential candidates for vaccine
design. One example of a website that provides tools for epitope prediction can be found
at http://www.immuneepitope.org/.
Based on a review by Tong et al. (2006), several methods and protocols have been
presented to predict immunogenic epitopes and they are generally classified into two main
categories; methods that are based on the pattern identification in sequences of binding
peptides and methods that model peptide with MHC interactions based on their three-
dimensional (3D) structures. Examples of the former category would be hidden Markov
models, artificial neural networks, procedures based on binding motifs, decision trees,
and support vector machines. Examples of the latter category would include the use of
homology modeling, docking and 3D techniques (Tong et al., 2006).
Computer predictions of MHC Class II-binding peptides can be used as a first screen-
ing method to determine what peptide sequences will induce a response. One of the tech-
niques which has been used in regards to prediction of MHC-binding peptides is hidden
Markov model (HMM) (Mamitsuka, 1998; Noguchi et al., 2002).
A Markov model consists of a set of states, in the case of biological sequence, those
states can either be the four DNA nucleotides (A, C, G and T) or the twenty amino acids.
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The outcome of an event in a Markov model depends only on the preceding state. Figure
2.2 uses DNA as an example for simplicity purposes.
Originally developed for speech recognition, HMMs have since been extensively used
in computational gene finding. HMM is a stochastic model, and is suitable for the rep-
resentation of time-series biological sequences with flexible lengths (Mamitsuka, 1998;
Tong et al., 2006). In biology, a hidden Markov model can be used to assign a state to
each residue in a sequence (Lund et al., 2005). An example is the B cell epitope model
(Figure 2.3) where the positions in a protein is divided into two states; epitope or non-
epitope. This information is kept hidden by the model where only the amino acid can be
observed. The twenty amino acids have been identified to belong to three groups accord-
ing to this model and they are hydrophobic [ACFILMPVW], uncharged polar [GNQSTY]
and charged [DEHKR].
Profile HMM (pHMM) is a type of hidden Markov model that fits the modelling of
multiple alignments (Durbin et al., 1998) and is used to characterize sequence similar-
ities within a family of proteins using the multiple sequence alignment of the protein
sequences. One criteria of profile HMM is to take into account the gaps that occur at each
of the position in the alignment. Profile HMMs also takes in the information of where
these gaps are more or less likely to occur from the alignment (Durbin et al., 1998). The
probability of a given residue existing at a particular position in the alignment is assigned
an emission probability, and the probability of the gaps provides position sensitive gap
scores. The approach taken to building a profile HMM as described by Durbin et al.
(1998) is the HMM is first built with repetitive states called the match states and all the
transition probability is assigned as one. When dealing with gaps, insertions and dele-
tions are treated individually. Sections of the sequence that do not match the model is
introduced as an insert state and sections in the alignment that do not match any of the
residues in a sequence is known as a delete state. Figure 2.4 shows a full profile HMM
with the three states; match, insert and delete. Between these three states, transition can
occur between two match states (m→ m), a match and an insert (m→ i), a match and a
delete (m→ d), an insert and a match (i→ m).
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Figure 2.2: On the left is a basic Markov model using DNA as the states. Transition from one state to
another (depicted by the arrow) is assigned a transition probability. Beginning (B) and end (E) states are
treated as silent states and are added for modeling both ends of a sequence. These states do not emit any
sequence.
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Figure 2.3: A B cell HMM model with two hidden states, epitope and non-epitope. The transition proba-
bility (represented by the arrow) is the probability of the epitope state transitioning to the non-epitope state
or to itself, or the other way around. The observation is represented by the emission probability and this is
given by the three groups of amino acid; hydrophobic (H), uncharged (U) and charged (C).
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Figure 2.4: Profile hidden Markov model consisting of three states; match, insert and delete. The insert
and match states have emission probabilities in general. Arrows from each state are assigned a transition
probability. The begin and end state are silent states and only serves as a start and end point.
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Probabilistic models such as this produces different outcomes with different proba-
bilities and the parameters can be estimated from large sets of trusted examples called a
training set (Durbin et al., 1998). The training set can provide a reasonable estimate of
the underlying probabilities of the model as long as it is not biased towards a particular
residue composition. Profile HMMs can reveal important details such as amino acid con-
servation, mutations, and active sites (Lund et al., 2005). Another application in biology
using profile HMM suggests the removal of redundant sequences (with a 90% similarity
over 90% of their length) from the training set (Singh et al., 2009).
For this study, the software HMMER3, which is available for online use or download
at http://hmmer.janelia.org/ is used to train and build the HMM. HMMER3
takes in a multiple sequence alignment of DNA or proteins as input. It uses a heuristic
algorithm called the multiple segment Viterbi (MSV) (Eddy, 2011) which is the dynamic
programming algorithm doing the alignment of the sequence to the HMM.
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Chapter 3
Method
3.1 Obtaining dataset and preprocessing of dataset
The MHC binding peptides dataset were downloaded from the Dana-Farber Reposi-
tory for Machine Learning in Immunology (http://bio.dfci.harvard.edu/
DFRMLI/). At the time of download, it contained 13,423 peptide sequences known to
bind to MHC molecules. Information related to peptide sequence such as binding affinity
(little, moderate, high) and MHC specificity (Class I, Class II) were also included in the
dataset. For the purpose of this study, only peptides that were known to have a high bind-
ing affinity to MHC Class II were extracted using Perl. The peptides were then separated
into its respective HLA group (Table 3.1). Two datasets were selected based on the higher
number of sequences, HLA-DR1 (403 peptide sequences) and HLA-DR4 (313 peptide
sequences). The peptide sequences were from different sources and some of them include
organisms such as parasites (Plasmodium falciparum), phages, toxins (tetanus toxin) and
viruses (hepatitis B virus).
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Table 3.1: Dataset of peptides with positive binding to MHC Class II obtained from MHCPEP.
Total sequence High binding sequence
HLA-DR1 1761 403
HLA-DR2 326 34
HLA-DR4 1187 313
HLA-DR7 360 39
HLA-DR11 482 68
HLA-DR15 127 46
HLA-DR17 167 33
HLA-DR51 143 39
HLA-DQ2 115 47
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Each dataset was then filtered to remove redundancy. Sequences more similar than
100%, 95% and 90% were eliminated (Table 3.2) using a web-based program called
ElimDupes (http://hcv.lanl.gov/content/sequence/ELIMDUPES/
elimdupes.html). For example, when a filtering parameter of 90% is set, if more
than 90% of the length of a shorter sequence is covered by a larger sequence, it is
considered a duplicate and removed from the dataset. There were no sequence set for
sequences with more than 95% similarity for the HLA-DR1 dataset. This produces a
total of seven sets of data to proceed with multiple sequence alignment, including the
original sets of sequence with no filtering.
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Table 3.2: Preprocessing of dataset
Dataset filter (%) n sequence
HLA-DR1 - 403
100 309
90 206
HLA-DR4 - 313
100 251
95 248
90 175
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3.2 Multiple sequence alignment and building of profile
HMM
Multiple sequence alignment was carried out using ClustalX (Larkin et al., 2007). The
protein weight matrix used was the default matrix, the Gonnet series. Each of the align-
ment file was then used to build a profile HMM using hmmbuild in HMMER3. The
alignment file was in fasta format and this had to be specified when running the hmm-
build program in the terminal:
$hmmbuild −−informat afa <output.hmm> <input.fasta>
hmmbuild will produce an output file which can be viewed using a text editor. The .hmm
file is divided into two regions; the first containing textual information and miscellaneous
parameters and the second containing a tabular format for the main model parameters.
The consensus sequence was derived using the hmmemit program where the consen-
sus parameter was stated in the command line at the terminal:
$hmmemit -c <hmmfile>
3.3 Evaluation of profile HMM using specificity study
For each profile HMM, a specificity study was carried out to determine whether the pro-
file HMM could identify the sequences that would fit the model. This was done using the
hmmsearch program in HMMER3. This program searches a profile against a sequence
database. For the purpose of the specificity study, a dummy sequence database was gen-
erated for each profile HMM. Each dummy database contained 500 peptide sequences,
450 of which were considered to be synthetic true positives (TP) generated using the hm-
memit program in HMMER3. This program samples sequences from the profile HMM
and outputs them. The number of sequences were specified when running the hmmemit
program in the terminal:
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$hmmemit -N 450
The remaining fifty sequence were considered as true negatives (TN) and were taken from
the MHCPEP dataset. The peptides selected were peptide sequences recorded as peptides
with little binding to MHC molecules. The profile HMM and the corresponding dummy
sequence database were then used in hmmsearch:
$hmmsearch <hmmfile> <seqdb>
The output ranks the list of sequences with the most significant matches to the profile.
The specificity of the profile HMM was then calculated using the ratio of the TN against
the total of TN and FP (false positives) as a probability that the sequence has little binding
affinity to the MHCmolecule when it is a sequence with little binding affinity to the MHC
molecule.
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Chapter 4
Results
Figure 4.1 is a section of the multiple sequence alignment for the DR1-od dataset (403
peptide sequences). This dataset came from the HLA-DR1 group and is the alignment of
the sequences with no filtering done (the naming convention DR1-od is used to refer to
the original dataset). Figure 4.2 is a section of the multiple sequence alignment for the
DR1-90 dataset (206 peptide sequences). This dataset came from the HLA-DR1 group
and is the alignment of the sequences with the filtering parameter of 90% (the naming
convention DR1-90 is used for this set). This means that if more than 90% of the length
of a shorter sequence is covered by a larger sequence, it is considered a duplicate and
removed from the dataset before it is aligned. Figure 4.3 is a section of the multiple
sequence alignment for the DR4-od dataset (313 peptide sequences). This dataset came
from the HLA-DR4 group and is the alignment of the sequences with no filtering done.
Figure 4.4 is a section of the multiple sequence alignment for the DR4-90 (175 peptide
sequences) dataset. This dataset came from the HLA-DR4 group and is the alignment of
the sequences with the filtering parameter of 90%. For full figures of the multple sequence
alignments, refer to Supplementary Material.
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Figure 4.1: A section of the multiple sequence alignment for DR1-od
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Figure 4.2: A section of the multiple sequence alignment for DR1-90
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Figure 4.3: A section of the multiple sequence alignment for DR4-od
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Figure 4.4: A section of the multiple sequence alignment for DR4-90
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Table 4.1 is a summary of the profile HMM for all seven datasets. The profile HMM
was named according to the HLA group it belongs to as well as the filtering parameter
used for that dataset. The aligned column was derived from the multiple sequence align-
ment which HMMER turned into a model of consensus positions. The difference between
aligned column and consensus sequence would be the gap-containing alignment columns
to be insertions relative to consensus.
Table 4.2 shows the consensus sequence derived from each of the profile HMM. The
residue distribution for hydrophobic (ACFILMPVW), uncharged polar (GNQSTY) and
charged (DEHKR) residues were calculated for each of the consensus sequence.
Figure 4.5 - figure 4.8 is the profile HMM and sequence logo for each of the dataset.
The profile HMM was viewed using HMMVE v1.2 : A Visual Editor for Profile Hidden
Markov Model (Dai & Cheng, 2008). Below the profile HMM is the sequence logo us-
ing the online version of LogoMAT-M (http://www.sanger.ac.uk/cgi-bin/
software/analysis/logomat-m.cgi). Sequence logos are used to illustrate the
content and distribution of a multiple alignment. LogoMAT-M is a type of sequence logo
used to view the distribution of a profile HMM. In the case of a protein alignment, the
residues are shown as a stack of letters. The letter at the top of the stack has the highest
probability, and the probability reduces going down the stack. The size of the letter also
contains information; it depicts the emission probability from the distribution of the state.
The width of the column shows the relative contribution of the position to the overall
model. The pink columns will most probably not contain any letters and these are the
insert states. The residues in LogoMAT-M are color-coded according to their biologi-
cal properties; charged [DEHKR], polar, uncharged [CNPQST], aliphatic [AGILVM] and
aromatic [FWY].
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Table 4.2 is the result of using hmmsearch to evaluate each profile HMM. The number
of targets above threshold is the number of sequences from the sequence database (the
dummy dataset consisting of 450 synthetic true positives and 50 true negatives) that the
profile HMM was searched against that made it through HMMER3’s filters. Based on the
two E-values produced in the output of hmmsearch, if both conditional and independent
E-values were significant (less than 1), the sequence is likely to be homologous to the
query. All the targets from the dummy dataset which were above the threshold had E-
values which were significant. From here, the specificity study was carried out, and each
profile HMM scored a probability of one.
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Table 4.3: Evaluation of profile HMM using hmmsearch
Dataset Number of targets above threshold
DR1-od 11
DR1-100 4
DR1-90 3
DR4-od 297
DR4-100 361
DR4-95 398
DR4-90 411
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Chapter 5
Discussion
The profile HMM method relies on the quality of the training data being used (Durbin
et al., 1998) as well as the quality of the multiple sequence alignment (Eddy, 1998). The
scoring method is based on the true frequency of a residue at a given position in the
alignment from its observed frequency. Therefore, redundancies within the dataset must
be eliminated in order to avoid bias towards the composition of a particular residue at a
particular position.
The HLA-DR1 group was divided according to two different filters; 100% (DR1-100)
and 90% (DR1-90). The HLA-DR4 group was divided according to three different filters;
100% (DR4-100), 95% (DR1-95) and 90% (DR4-90). Each dataset, including the original
dataset (DR1-od and DR4-od), was submitted for a multiple sequence alignment and from
there the profile HMM was built. Despite coming from the same group, DR1-od, DR-100
and DR1-90 produced different profile HMMs. The number of consensus sequence vary
slightly (21 for DR1-od, 24 for DR1-100, 22 for DR1-90). These consensus positions
also correlate with the match states of the profile HMM. This shows that the training set
as well as the multiple sequence alignment will affect the building of the profile HMM due
to the contribution of a particular residue at a particular position. Same goes for the HLA-
DR4 group. The number of consensus sequence vary slightly as well (34 for DR4-od, 38
for DR4-100, 36 for DR4-95, 41 for DR4-90). Another trend which can be observed is
the number of gap-containing alignment. The gap-containing alignment decreases when
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more stringent parameters are used. For the HLA-DR1 group, the DR1-od has 16 gaps,
DR1-100 has 10 gaps, DR1-90 has 13 gaps. For the HLA-DR4 group, the DR4-od has 8
gaps, DR1-100 has 6 gaps, DR4-95 has 9 gaps, DR-90 has 6 gaps.
Based on the consensus sequence of all the datasets, the residue distribution for hy-
drophobic, uncharged polar and polar was calculated. All seven consensus sequences
showed a high content of hydrophobic residues. For datasets in each of the HLA group
(HLA-DR1 and HLA-DR4), although the consensus sequence differed from one another,
the content for hydrophobic residues is the highest for all the datasets.
Based on the specificity study carried out, it was apparent that the profile HMM is
able to differentiate between the true positive sequences with the true negatives. In fact,
the specificity study carried out [TN ÷ (TN + FP)] showed that all seven datasets had a
probability of one. From the sequence targets identified to be homologous to the profile,
none of the true negative was in the output. A possible explanation for this would be
due to the fact that the true positives were generated based on the profile HMM model
itself. These results might not reflect a realistic situation due to the bias. Possible future
work to rectify this would be to increase the number of dataset to include actual validated
experimental data so as to improve the reliability of the test dataset.
Due to the fact that the profile HMMmethod is still a statistical method, it is important
to determine the biology knowledge behind the application. A profile HMM can always
be built using a multiple sequence alignment, but more information is needed to make
it a meaningful one. Letting the model train itself can be used at a preliminary stage of
analysis, but must later on be incorporated with the biological knowledge relevant to the
problem being asked. Information such as structural characteristic of the amino acid can
be included to build a better profile HMM. The MHC Class II binding groove has been
proposed to consist of only 9 residues. In order to provide a better profile HMM for MHC
Class II binding peptides, these information should be incorporated so as to produce more
realistic results.
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Chapter 6
Conclusion
Based on the basic analysis done on HMM profiles generated by HMMER3 on the two
group of MHC-binding dataset (HLA-DR1 and HLA-DR4), there is still much to be in-
vestigated. Most importantly is the biological background of the profile HMM for MHC-
binding peptides. Further investigation of the correlation between biological properties of
the amino acid such as hydrophobic, aliphatic and uncharged polar of the peptides need
to be studied. An example is the B cell HMM model where the basic distribution of the
amino acids have been characterized (Figure 2.3).
Profile HMM is a good method for finding similarities between distantly related se-
quences of varying lengths. An important thing to note is the training data used for build-
ing the profile HMM; the training set can provide a reasonable estimate of the underlying
probabilities of the model provided that it is not biased towards a particular residue com-
position.
In order for this method to be included in the pipeline for vaccine design, a more
careful analysis needs to be done. Based on this preliminary study, it has the potential to
be investigated further for future research.
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